Jump to main content
Takeda will discontinue global manufacturing of NATPARA by the end of 2024. Learn How This May Affect You
NATPARA logo.

NATPARA® is a parathyroid hormone indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism. Because of the potential risk of osteosarcoma, NATPARA is recommended only for patients who cannot be well-controlled on calcium supplements and active forms of vitamin D alone. NATPARA was not studied in patients with hypoparathyroidism caused by calcium-sensing receptor mutations. NATPARA was not studied in patients with acute post-surgical hypoparathyroidism.

See full indication

See less indication

NATPARA® is a parathyroid hormone indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism. Because of the potential risk of osteosarcoma, NATPARA is recommended only for patients who cannot be well-controlled on calcium supplements and active forms of vitamin D alone. NATPARA was not studied in patients with hypoparathyroidism caused by calcium-sensing receptor mutations. NATPARA was not studied in patients with acute post-surgical hypoparathyroidism.

See full indication

See less indication

NATPARA logo.

NATPARA Administration Kit Components

The Mixing Device and Q-Cliq™ Pen

The mixing device and Q-Cliq pen.

NATPARA Medication Cartridges are designed for use with the following:

  • Reusable Mixing Device for product reconstitution
  • Reusable Q-Cliq pen(s) for drug delivery

The Q-Cliq pen is designed to deliver a fixed dose and can be used for up to 2 years of daily treatment. The NATPARA Medication Cartridge(s) should be discarded on the 15th day, following two weeks (14 days) of treatment.1

NATPARA Q-Cliq pen needle.

31G x 8mm

BD Ultra-Fine™ Pen Needle

The needle is approximately the width of two human hairs.2,3

Download
Instructions for Use

Additional supplies

The NATPARA Administration Kit will also include:

  • Disposable needles
  • Alcohol swabs
  • NATPARA Medication Cartridge Tracker

A puncture-resistant container (“sharps” container) is also required, but it is not provided in the NATPARA Administration Kit.

References: 1. NATPARA [package insert]. Shire Pharmaceuticals, Inc. 2. Sigma-Aldrich Co. LLC. Syringe needle gauge chart. Sigma-Aldrich Website. http://www.sigmaaldrich.com/chemistry/stockroom-reagents/learning-center/technical-library/needle-gauge-chart.html. Accessed April 24, 2017. 3. US Department of Energy. The scale of things – nanometers and more. National Nanotechnology Infrastructure Network Website. http://www.nnin.org/sites/default/files/files/scale_of_things_26may06.pdf. Accessed April 24, 2017.

NATPARA® and the NATPARA Logo® are registered trademarks of Takeda Pharmaceuticals, U.S.A,. Inc.

Takeda logo.

©2025 Takeda Pharmaceuticals U.S.A., Inc., 500 Kendall Street, Cambridge, MA 02142. 1-877-TAKEDA-7 (1-877-825-3327). All rights reserved. Takeda and the Takeda Logo are registered trademarks of Takeda Pharmaceutical Company Limited.
US-NAT-0590v1.0 01/25

All content in this site, including text, images, graphics, sound files, and their arrangement, is copyrighted and owned by Takeda and is protected by international copyright laws. All other intellectual property rights are reserved. The content may not be copied for commercial use or distribution, nor may these objects be downloaded, modified, or posted to other sites.

This site is intended solely for US residents and is governed solely by US laws and government regulations. Please see our Legal Notice for more information. While Takeda Pharmaceutical Company Limited makes reasonable efforts to include accurate, up-to-date information on this site, Takeda Pharmaceutical Company Limited makes no warranties or representations as to its accuracy. Takeda Pharmaceutical Company Limited assumes no liability for any errors or omissions in the content of this site.